SUN-P183: Fatty Liver Index for Predicting Non-Alcoholic Fatty Liver Disease Based On Cap Grading

Background and aims. We aimed to study prevalence and the predictive factors of non-alcoholic fatty liver disease (NAFLD) defined by the fatty liver index (FLI) in type 2 diabetic patients (T2DM).Methods. Three hundred and eighty-one T2DM outpatients who regularly attended a Consulting Clinic in Cluj were retrospectivelly included. FLI, a surrogate steatosis biomarker based on body mass index (BMI), waist circumference (WC), triglycerides (TGL) and gammaglutamyl-transferase (GGT) was used to assess NAFLD in all patients. Anthropometric and biochemical parameters were measured. Hepatic steatosis (HS) was evaluated by ultrasonography.Results. NAFLD-FLI (defined as FLI >60) was correlated with HS evaluated by ultrasound (r=0.28; p<0.001). NAFLD-FLI was detected in 79% of T2DM. The prevalence of obesity in NAFLD-FLI patients was 80%. Of the patients with normal alanine aminotransferase (ALAT), 73.8 % had NAFLD. At univariate analysis, NAFLD-FLI was correlated with age (r= -0.14; p=0.007), sex (r=0.20; p<0.001), LDL cholesterol (r=0.12; p=0.032), HDL cholesterol (r = -0.13; p=0.015), ALAT (r=0.20; p<0.001) and ASAT (r=0.19; p<0.001). At multiple regression analysis, sex, ALAT and LDL-cholesterol were independent predictors of NAFLD-FLI. After logistic regression model, ALAT, LDL-cholesterol, HOMA-IR were good independent predictors of NAFLD-FLI.Conclusions. NAFLD-FLI could be useful to identify NAFLD in T2DM patients. Subjects with T2DM had a high prevalence of NADLD-FLI even with normal ALAT levels . Our findings showed that sex, ALAT, LDL cholesterol and IR were significant and independent factors associated with the presence of NAFLD in T2DM subjects.

Download Full-text

Validation of Fatty Liver Index as a Marker for Non-Alcoholic Fatty Liver Disease

Korean Journal of Health Promotion ◽

10.15384/kjhp.2021.21.2.56 ◽

2021 ◽

Vol 21 (2) ◽

pp. 56-62

Author(s):

Seong-Won Park ◽

A-Lum Han

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Health Examination ◽

Cross Sectional ◽

Alcoholic Fatty Liver ◽

Nonalcoholic Fatty Liver ◽

Liver Index ◽

Fatty Liver Index ◽

Alcoholic Fatty Liver Disease

Background: Many studies have been conducted to validate fatty liver index (FLI) as a marker for non-alcoholic fatty liver disease (NAFLD). However, there are insufficient data in Korea to verify the usefulness of FLI, and the results of these studies are contradictory. This study aimed to validate FLI as a marker for NAFLD in Korea. For better accuracy, computed tomography (CT) scan was used instead of ultrasound scan.Methods: A cross-sectional analysis was performed in 785 subjects who participated in a health examination. The participants were divided according to presence of NAFLD, which was determined by abdominal CT. Frequency analysis was performed on all results. The chi-square test and independent t-test were used to compare the differences between the non-NAFLD group and the NAFLD group in terms of general characteristics and blood tests. The ability of the FLI to detect (nonalcoholic) fatty liver was assessed using area under the receiver operator characteristic (AUROC) curve analysis.Results: FLI was significantly higher in the NAFLD group (42.48±27.63) than in the non-NAFLD group (22.59±20.05) (P<0.0001). The algorithm for FLI had a better AUROC of 0.696 (95% confidence interval, 0.649-0.742) than any other variable in the prediction of NAFLD.Conclusions: FLI is a marker that can be used as a simple and cost-effective tool to screen for NAFLD.

Download Full-text

Fatty Liver Index (FLI) in Predicting Non-alcoholic Fatty Liver Disease (NAFLD)

Hepatitis Monthly ◽

10.5812/hepatmon.63227 ◽

2018 ◽

Vol 18 (2) ◽

Cited By ~ 2

Author(s):

Zahra Dehnavi ◽

Farkhonde Razmpour ◽

Mahmoud Belghaisi Naseri ◽

Mohsen Nematy ◽

Seyed Ali Alamdaran ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Liver Index ◽

Fatty Liver Index ◽

Alcoholic Fatty Liver Disease

Download Full-text

683 Assessment of Fatty Liver Index (FLI) for the Diagnosis of Non-Alcoholic Fatty Liver Disease (NAFLD) in Morbidly Obese Patients

Gastroenterology ◽

10.1016/s0016-5085(13)60450-3 ◽

2013 ◽

Vol 144 (5) ◽

pp. S-125 ◽

Cited By ~ 1

Author(s):

J. Michael Estep ◽

Nayeem Hossain ◽

Munkhzul Otgonsuren ◽

Elena Younossi ◽

Heshaam M. Mir ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Morbidly Obese ◽

Obese Patients ◽

Alcoholic Fatty Liver ◽

Liver Index ◽

Fatty Liver Index ◽

Alcoholic Fatty Liver Disease

Download Full-text

Fatty liver index (FLI) and prediction of new cases of non-alcoholic fatty liver disease: A population-based study of northern Iran

Clinical Nutrition ◽

10.1016/j.clnu.2019.02.024 ◽

2020 ◽

Vol 39 (2) ◽

pp. 468-474 ◽

Cited By ~ 2

Author(s):

Nima Motamed ◽

Amir Hossein Faraji ◽

Mahmood Reza Khonsari ◽

Mansooreh Maadi ◽

Fahimeh Safarnezhad Tameshkel ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Population Based ◽

Northern Iran ◽

Population Based Study ◽

Alcoholic Fatty Liver ◽

Liver Index ◽

Fatty Liver Index ◽

Alcoholic Fatty Liver Disease

Download Full-text

An extended fatty liver index to predict non-alcoholic fatty liver disease

Diabetes & Metabolism ◽

10.1016/j.diabet.2016.11.006 ◽

2017 ◽

Vol 43 (3) ◽

pp. 229-239 ◽

Cited By ~ 13

Author(s):

K. Kantartzis ◽

I. Rettig ◽

H. Staiger ◽

J. Machann ◽

F. Schick ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Liver Index ◽

Fatty Liver Index ◽

Alcoholic Fatty Liver Disease

Download Full-text

Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)

Annals of Medicine ◽

10.1080/07853890.2021.1956685 ◽

2021 ◽

Vol 53 (1) ◽

pp. 1256-1264

Author(s):

Daniel J. Cuthbertson ◽

Juha Koskinen ◽

Emily Brown ◽

Costan G. Magnussen ◽

Nina Hutri-Kähönen ◽

...

Keyword(s):

Type 2 Diabetes ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Alcoholic Fatty Liver ◽

Liver Index ◽

Fatty Liver Index ◽

Alcoholic Fatty Liver Disease

Download Full-text

Abstract 16988: Fatty Liver Index is Reduced With Ezetimibe in an Analysis of 15,095 Patients Randomized to Ezetimibe vs Placebo in the Improve-it Trial

Circulation ◽

10.1161/circ.132.suppl_3.16988 ◽

2015 ◽

Vol 132 (suppl_3) ◽

Author(s):

Tracey G Simon ◽

Jeong-Gun Park ◽

Kathleen E Corey ◽

Raymond T Chung ◽

Christopher P Cannon ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Pharmacologic Therapy ◽

Alcoholic Fatty Liver ◽

Liver Index ◽

Fatty Liver Index ◽

Increased Risk ◽

The Impact ◽

Alcoholic Fatty Liver Disease

Background: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the US, and is associated with early atherogenesis and increased risk of cardiovascular (CV) death. Although no pharmacologic therapy has proven benefit in NAFLD, recent clinical studies suggest that ezetimibe may reduce histologic evidence of liver inflammation and improve serum markers of NAFLD. In this post hoc analysis of the IMPROVE-IT trial, we assessed the impact of ezetimibe in patients with presumed NAFLD, using the Fatty Liver Index (FLI), a validated prediction score for hepatic steatosis. Methods: Of the 18,144 IMPROVE-IT patients randomized to ezetimibe/simvastatin (E/S) or placebo/simvastatin (P/S), 15,095 had both baseline ALT 2x ULN and sufficient data with which to calculate FLI, a calculated score composed of triglycerides (TG), gamma-glutamyltransferase (GGT), body mass index (BMI), and waist circumference. FLI ≥ 60 has been strongly correlated with NAFLD, while values <30 indicate low probability of NAFLD. Differences in FLI between treatment arms over time were tested with non-parametric Wilcoxon rank-sum tests. Results: Baseline FLI was ≥ 60 in 6798 (45%) patients and <30 in 3438 (23%). E/S reduced median absolute FLI from 55.0 to 51.2 over 72 months, a reduction of 6.9%, which was significantly greater than that observed in P/S group (all p<0.001 at each time-point, Fig). Of those with initial FLI ≥ 60 treated with E/S, 26.3% had 48-month FLI score < 60 (compared to 21.6% in P/S group, p<0.001). E/S significantly reduced both TG and GGT compared to P/S (both p<0.001 at 72 months). E/S significantly reduced FLI regardless of baseline ALT (normal vs. 1-2x ULN) ( p =0.002; interaction p =0.53). Conclusion: Ezetimibe significantly reduced surrogate markers of NAFLD, suggesting that it may offer protection against progression of non-alcoholic fatty liver disease, metabolic syndrome, and atherogenic risk.

Download Full-text